Halozyme Therapeutics (NEO:HALO) and 138267 (COM.TO) (TSE:COM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Earnings & Valuation
This table compares Halozyme Therapeutics and 138267 (COM.TO)'s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Halozyme Therapeutics | C$267.59 million | 24.79 | C$130.40 million | C$0.91 | 50.88 |
138267 (COM.TO) | N/A | N/A | N/A | N/A | N/A |
Halozyme Therapeutics has higher revenue and earnings than 138267 (COM.TO).
Analyst Recommendations
This is a summary of recent ratings and price targets for Halozyme Therapeutics and 138267 (COM.TO), as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Halozyme Therapeutics | 0 | 0 | 0 | 1 | 4.00 |
138267 (COM.TO) | 0 | 0 | 0 | 0 | N/A |
Halozyme Therapeutics presently has a consensus target price of C$0.27, suggesting a potential downside of 99.42%.
Profitability
This table compares Halozyme Therapeutics and 138267 (COM.TO)'s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Halozyme Therapeutics | N/A | N/A | N/A |
138267 (COM.TO) | N/A | N/A | N/A |
Summary
Halozyme Therapeutics beats 138267 (COM.TO) on 2 of the 2 factors compared between the two stocks.